Mobile

A study evaluating venetoclax (ABT-199) in subjects with Chronic Lymphocytic Leukemia (CLL) whose cancer has come back or who had no response to previous cancer treatments including subjects who may b...

Mise à jour : Il y a 4 ans
Référence : EUCTR2015-003667-11

A study evaluating venetoclax (ABT-199) in subjects with Chronic Lymphocytic Leukemia (CLL) whose cancer has come back or who had no response to previous cancer treatments including subjects who may be missing part of their chromosome 17 identified as 17p deletion, or TP53 gene mutation; or subjects who did not respond to or did not tolerate treatment with B-cell receptor inhibitors

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

The primary objective of this study to evaluate the efficacy of venetoclax monotherapy in subjects with relapsed or refractory chronic lymphocytic leukemia (CLL) including those with the 17p deletion or TP53 gene mutations or in CLL subjects who are refractory or intolerant to B-Cell receptor inhibitor (BCRi) therapy.

Critère d'inclusion

  • Chronic lymphocytic leukemia

Liens